Abstract
Aim:
To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models.
Methods:
The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg−1·d−1 and 100 mg·kg−1·d−1) groups and an Aricept (2 mg·kg−1·d−1) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris water-maze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot.
Results:
In Morris water-maze test, evodiamine (100 mg·kg−1·d−1) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg−1·d−1) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease.
Conclusion:
The results indicate that evodiamine (100 mg·kg−1·d−1) improves cognitive abilities in the transgenic models of Alzheimer's disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mattson MP . Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631–9.
Hardy J, Selkoe DJ . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–6.
Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ . The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006; 113: 1685–95.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216–23.
McGeer EG, McGeer PL . Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741–9.
Heneka MT, O'Banion MK . Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69–91.
Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB . Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39: 1–16.
Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007; 69: 275–82.
Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009; 80: 268–73.
Butterfield DA, Poon HF . The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol 2005; 40: 774–83.
Miyamoto M . Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp Gerontol 1997; 32: 139–48.
Flood JF, Morley JE . Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 1998; 22: 1–20.
Kim HK, Kim M, Kim S, Kim M, Chung JH . Effects of green tea polyphenol on cognitive and acetylcholinesterase activities. Biosci Biotechnol Biochem 2004; 68: 1977–9.
Lu JH, Guo J, Yang WH . Effects of green tea polyphenol on the behaviour of Alzheimer' s disease like mice induced by D-galactose and Abeta25-35 . Zhong Yao Cai 2006; 29: 352–4.
Marambaud P, Zhao H, Davies P . Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377–82.
Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE . Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54: 111–8.
Sehirli O, Tozan A, Omurtag GZ, Cetinel S, Contuk G, Gedik N, et al. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol Environ Saf 2008; 71: 301–8.
Lee SH, Son JK, Jeong BS, Jeong TC, Chang HW, Lee ES, et al. Progress in the studies on rutaecarpine. Molecules 2008; 13: 272–300.
Wang L, Hu CP, Deng PY, Shen SS, Zhu HQ, Ding JS, et al. The protective effects of rutaecarpine on gastric mucosa injury in rats. Planta Med 2005; 71: 416–9.
Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T . Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001; 67: 628–33.
Cox MM, Tucker AM, Tang J, Talbot K, Richer DC, Yeh L, et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav 2009; 8: 390–7.
Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 2009; 156: 982–93.
Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381–8.
Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 2004; 165: 987–95.
Yu AS, Lin HD, Huang SC, Phelps ME, Wu HM . Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med 2009; 50: 966–73.
Chow PL, Rannou FR, Chatziioannou AF . Attenuation correction for small animal PET tomographs. Phys Med Biol 2005; 50: 1837–50.
Blass JP . Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001; 66: 851–6.
Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, et al. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 1999; 48: 1532–5.
Yoshizumi M, Houchi H, Ishimura Y, Hirose M, Kitagawa T, Tsuchiya K, et al. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest 1997; 44: 79–82.
Chiou WF, Chou CJ, Shum AY, Chen CF . The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 1992; 215: 277–83.
Kobayashi Y . The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med 2003; 69: 425–8.
King CL, Kong YC, Wong NS, Yeung HW, Fong HH, Sankawa U . Uterotonic effect of Evodia rutaecarpa alkaloids. J Nat Prod 1980; 43: 577–82.
Jiang J, Hu C . Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 2009; 14: 1852–9.
Liu YN, Pan SL, Liao CH, Huang DY, Guh JH, Peng CY, et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock 2009; 32: 263–9.
Ko HC, Wang YH, Liou KT, Chen CM, Chen CH, Wang WY, et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 2007; 555: 211–7.
Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20: 149–55.
Vallieres L, Rivest S . Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J Neurochem 1997; 69: 1668–83.
Gruol DL, Nelson TE . Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997; 15: 307–39.
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22–8.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383–421.
O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD . Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996; 66: 2532–40.
Yamamoto K, Arakawa T, Ueda N, Yamamoto S . Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315–20.
Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T . Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009; 87: 181–94.
Acknowledgements
The present work was supported in part by the Ministry of Health Foundation (No 200802036) and the National Science and Technology Major Projects (No 2009ZX09501-026).
The authors appreciate that Dr JAMES improved the expression of English and the figures.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yuan, Sm., Gao, K., Wang, Dm. et al. Evodiamine improves congnitive abilities in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models of Alzheimer's disease. Acta Pharmacol Sin 32, 295–302 (2011). https://doi.org/10.1038/aps.2010.230
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2010.230
Keywords
This article is cited by
-
Evodiamine Relieve LPS-Induced Mastitis by Inhibiting AKT/NF-κB p65 and MAPK Signaling Pathways
Inflammation (2022)
-
Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus
Scientific Reports (2019)
-
Protective effects of evodiamine in experimental paradigm of Alzheimer’s disease
Cognitive Neurodynamics (2018)
-
Development and Validation of a Rapid and Specific UHPLC–MS/MS Method for Simultaneous Determination of 21 Bioactive Components in Tiantai No. 1 Pill and Rat Plasma
Chromatographia (2018)
-
A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
Chemistry Central Journal (2016)
